7.515

4.04% 0.215

Lipocine Inc (LPCN)

Overview News Price History Financials Discussions Forecast Stock Split

Lipocine Inc stock is traded at $7.515, with a volume of 16,651. It is up +4.04% in the last 24 hours and up +141.11% over the past month. Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Previous Close:

$7.30

Open:

$7.29

24h Volume:

16,651

Relative Volume:

0.20

Market Cap:

$41.72M

Revenue:

Net Income/Loss:

$-16.35M

P/E Ratio:

-2.4639

EPS:

-3.05

Net Cash Flow:

$-11.88M

1W Performance:

+15.60%

1M Performance:

+141.11%

6M Performance:

+145.00%

1Y Performance:

+51.90%

1-Day Range:

$7.211

$7.63

1-Week Range:

$6.301

$8.3472

52-Week Range:

$2.52

$8.3472

Lipocine Inc Stock (LPCN) Company Profile

Name

Lipocine Inc

Sector

Healthcare (1119)

Industry

Biotechnology (624)

Phone

801 994 7383

Address

675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

LPCN's Discussions on Twitter

Compare LPCN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LPCN Lipocine Inc	7.515	40.53M	0	-16.35M	-11.88M	-3.05
VRTX Vertex Pharmaceuticals Inc	466.70	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.49	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	393.09	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.04	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.03	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-24-21	Initiated	Cantor Fitzgerald	Overweight
Dec-10-20	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-12-18	Reiterated	H.C. Wainwright	Buy
Jan-11-18	Downgrade	Canaccord Genuity	Buy → Hold
Dec-08-17	Resumed	H.C. Wainwright	Buy
Oct-07-16	Initiated	H.C. Wainwright	Buy
Jul-22-15	Initiated	ROTH Capital	Buy
Jun-23-15	Initiated	Canaccord Genuity	Buy

View All

Lipocine Inc Stock (LPCN) Latest News

Dec 26, 2025

Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World

Dec 26, 2025

Dec 24, 2025

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN

Dec 24, 2025

Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN

Dec 24, 2025

Dec 21, 2025

Aug PreEarnings: Can Lipocine Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда

Dec 21, 2025

Market Pulse: How Lipocine Inc. stock reacts to global recession fearsWeekly Trade Report & Long Hold Capital Preservation Tips - Улправда

Dec 21, 2025

How Lipocine Inc. stock reacts to global recession fears2025 Trading Volume Trends & AI Driven Price Predictions - Улправда

Dec 21, 2025

Dec 20, 2025

Can Lipocine Inc. stock outperform in 2025 bull marketMarket Sentiment Report & Weekly High Return Stock Opportunities - Улправда

Dec 20, 2025

Dec 19, 2025

Does Lipocine Inc. stock trade at a discount to peersJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда

Dec 19, 2025

Return on equity % of Lipocine Inc. – BOATS:LPCN - TradingView — Track All Markets

Dec 19, 2025

Big Money Moves: How Lipocine Inc. stock reacts to global recession fearsWeekly Investment Recap & Community Driven Trade Alerts - Улправда

Dec 19, 2025

Trend Review: Can Lipocine Inc. stock deliver consistent earnings growth2025 Valuation Update & Detailed Earnings Play Alerts - DonanımHaber

Dec 19, 2025

How Lipocine Inc. stock performs in high volatility marketsJuly 2025 Snapshot & Fast Gain Stock Trading Tips - DonanımHaber

Dec 19, 2025

Financial Review: Lipocine (NASDAQ:LPCN) vs. Astellas Pharma (OTCMKTS:ALPMY) - Defense World

Dec 19, 2025

Dec 16, 2025

Lipocine reaches 80% enrollment in postpartum depression drug trial By Investing.com - Investing.com Nigeria

Dec 16, 2025

Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks

Dec 16, 2025

Lipocine Inc Announces 80% Enrollment in PPD Phase 3 Study - TradingView — Track All Markets

Dec 16, 2025

Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com India

Dec 16, 2025

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire

Dec 16, 2025

Dec 15, 2025

Lipocine Inc. Announces Resignation of Jeffrey Fink as Director, Effective January 1, 2026 - marketscreener.com

Dec 15, 2025

Lipocine Earnings Notes - Trefis

Dec 15, 2025

Dec 11, 2025

Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting - Investing.com UK

Dec 11, 2025

Dec 03, 2025

EBIT per share of Lipocine Inc. – BOATS:LPCN - TradingView

Dec 03, 2025

Dec 01, 2025

Lipocine (LPCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 01, 2025

Nov 23, 2025